These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Carcinoembryonic antigen transgenic mouse models for immunotherapy and development of cancer vaccines. Bhattacharya-Chatterjee M; Saha A; Foon KA; Chatterjee SK Curr Protoc Immunol; 2008 Feb; Chapter 20():20.8.1-20.8.12. PubMed ID: 18432635 [TBL] [Abstract][Full Text] [Related]
3. Modeling pancreatic cancer in mice for experimental therapeutics. Mallya K; Gautam SK; Aithal A; Batra SK; Jain M Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847 [TBL] [Abstract][Full Text] [Related]
4. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321 [TBL] [Abstract][Full Text] [Related]
5. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297 [TBL] [Abstract][Full Text] [Related]
6. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023 [TBL] [Abstract][Full Text] [Related]
7. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy. Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683 [TBL] [Abstract][Full Text] [Related]
8. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
9. Mouse models in oncogenesis and cancer therapy. Céspedes MV; Casanova I; Parreño M; Mangues R Clin Transl Oncol; 2006 May; 8(5):318-29. PubMed ID: 16760006 [TBL] [Abstract][Full Text] [Related]
10. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy. Wege AK BioDrugs; 2018 Jun; 32(3):245-266. PubMed ID: 29589229 [TBL] [Abstract][Full Text] [Related]
11. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538 [TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
13. Large-cohort humanized NPI mice reconstituted with CD34 Xu X; Gu H; Li H; Gao S; Shi X; Shen J; Li B; Wang H; Zheng K; Shao Z; Cheng P; Cha Z; Peng S; Nie Y; Li Z; Guo S; Qian B; Jin G FASEB J; 2022 Apr; 36(4):e22244. PubMed ID: 35262964 [TBL] [Abstract][Full Text] [Related]
14. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641 [TBL] [Abstract][Full Text] [Related]
15. Mouse Models of Tumor Immunotherapy. Ngiow SF; Loi S; Thomas D; Smyth MJ Adv Immunol; 2016; 130():1-24. PubMed ID: 26922998 [TBL] [Abstract][Full Text] [Related]
16. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884 [TBL] [Abstract][Full Text] [Related]
17. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162 [TBL] [Abstract][Full Text] [Related]
18. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053 [TBL] [Abstract][Full Text] [Related]
19. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Saito R; Kobayashi T; Kashima S; Matsumoto K; Ogawa O Int J Clin Oncol; 2020 May; 25(5):831-841. PubMed ID: 31407168 [TBL] [Abstract][Full Text] [Related]
20. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Maccalli C; Parmiani G; Ferrone S Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]